Scarica l'app Stockscreener
435.52
0.35%
1.50
Dopo l'orario di chiusura:
435.52
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$434.02
Aprire:
$434
Volume 24 ore:
1.08M
Relative Volume:
0.72
Capitalizzazione di mercato:
$43.17B
Reddito:
$11.74B
Utile/perdita netta:
$3.68B
Rapporto P/E:
30.69
EPS:
14.1888
Flusso di cassa netto:
$3.34B
1 W Prestazione:
+1.47%
1M Prestazione:
+4.49%
6M Prestazione:
-0.71%
1 anno Prestazione:
-6.74%
Intervallo 1D:
$430.15
$437.79
Intervallo di 1 settimana:
$425.46
$442.22
Portata 52W:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Confronta VRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
435.52 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ARGX
Argen X Se Adr
|
918.53 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
201.62 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
363.92 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
725.34 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
How risky is Vertex Pharmaceuticals Incorporated (VX1) stock compared to peersWall Street Watch & Technical Entry and Exit Alerts - newser.com
A Look at Vertex Pharmaceuticals’s Valuation Following Promising Kidney Trial Updates and New FDA Designations - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings - Yahoo Finance
Vertex Pharmaceuticals Incorporated’s volatility index tracking explainedMarket Trend Review & Advanced Swing Trade Entry Alerts - newser.com
How Vertex Pharmaceuticals Incorporated (VX1) stock moves on employment dataTrade Volume Summary & Entry Point Strategy Guides - newser.com
Stifel Maintains Hold Rating on Vertex (VRTX), Keeps $445 Price Target - Insider Monkey
Published on: 2025-11-17 18:09:39 - newser.com
Vertex Pharmaceuticals Insider Sold Shares Worth $32,292,320, According to a Recent SEC Filing - MarketScreener
Is Vertex Pharmaceuticals Inc Gaining or Losing Market Support? - Benzinga
Published on: 2025-11-17 12:00:44 - newser.com
1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November - Finviz
Published on: 2025-11-16 17:26:31 - newser.com
Published on: 2025-11-16 14:03:23 - newser.com
Visual analytics tools that track Vertex Pharmaceuticals Incorporated performanceJuly 2025 Opening Moves & Technical Buy Zone Confirmations - newser.com
My 3 Favorite Stocks to Buy Right Now - Finviz
My 3 Favorite Stocks to Buy Right Now - The Motley Fool
Published on: 2025-11-16 04:54:52 - newser.com
Will Vertex Pharmaceuticals Incorporated benefit from macro trends2025 Growth vs Value & Daily Volume Surge Trade Alerts - newser.com
Is Vertex Pharmaceuticals Incorporated stock a smart buy before Fed meetingJuly 2025 Intraday Action & Daily Volume Surge Trade Alerts - newser.com
Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $500 From $430, Maintains Buy Rating - MarketScreener
Is Vertex Pharmaceuticals Incorporated (VX1) stock a buy on weaknessPortfolio Update Report & Breakout Confirmation Trade Signals - newser.com
Exit strategy if you’re trapped in Vertex Pharmaceuticals IncorporatedMarket Movement Recap & Verified Technical Signals - newser.com
Evercore ISI Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Novartis, Vertex, More Optimizing Shots on Multiple Goals in Lucrative I&I Space - BioSpace
Vertex Pharmaceuticals’ Promising Cystic Fibrosis Study: A Potential Game-Changer - MSN
Vertex highlights growing Medicaid coverage for non-opioid painkiller Journavx (VRTX:NASDAQ) - Seeking Alpha
Transcript : Vertex Pharmaceuticals Incorporated Presents at UBS Global Healthcare Conference 2025, Nov-09-2025 through Nov-12-2025 - MarketScreener
Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
The Bull Case for Vertex Pharmaceuticals (VRTX) Could Change Following Strong Kidney Data and Regulatory Progress - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and Insulet (PODD) - The Globe and Mail
Vertex Pharmaceuticals: Promising Growth in Renal Disease Market with Strong Clinical Data and Strategic Development - TipRanks
Vertex stock holds steady as Stifel maintains $445 price target By Investing.com - Investing.com UK
Vertex Pharmaceuticals’ Promising Renal Franchise Developments Justify Buy Rating - TipRanks
5 Insightful Analyst Questions From Vertex Pharmaceuticals's Q3 Earnings Call - Finviz
Vertex Pharma Q3 2025 Earnings: $3.08B Revenue, EPS $4.80, Updates GuidanceNews and Statistics - IndexBox
Published on: 2025-11-10 02:55:06 - newser.com
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q3 Earnings Call - The Globe and Mail
Can machine learning forecast Vertex Pharmaceuticals Incorporated recoveryJuly 2025 Reactions & Daily Profit Focused Stock Screening - newser.com
Vertex Pharmaceuticals (VRTX) Reports Promising Results from RUB - GuruFocus
Vertex Unveils Positive 48-Week Data For Povetacicept In IgAN And PMN - Nasdaq
Transcript : Vertex Pharmaceuticals IncorporatedSpecial Call - MarketScreener
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.14%
3.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):